Sign Up to like & get
recommendations!
0
Published in 2020 at "Gynecologic Oncology Reports"
DOI: 10.1016/j.gore.2020.100553
Abstract: Highlights • Effective treatment options for recurrent endometrial carcinomas are limited.• Immune checkpoint inhibitor is a recent progress in cancer immunotherapy.• Reports on recurrent endometrial carcinomas managed by pembrolizumab are limited.
read more here.
Keywords:
immune checkpoint;
regression microsatellite;
recurrent endometrial;
pembrolizumab ... See more keywords